Oral contraceptive use in perimenopause
review
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
This paper examines the use of oral contraceptives in perimenopausal women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Perimenopause represents a transition period lasting about 5 years before the permanent cessation of spontaneous menses. During this transition, the emphasis of clinical care changes. Although women still need effective contraception during perimenopause, issues including loss of bone mineral density, menstrual cycle changes, and vasomotor instability also need to be addressed. Hormone replacement therapy is not the first-line treatment for women with symptomatic perimenopause because hormone replacement therapy neither suppresses ovulation nor provides contraception; also, it will not prevent and in fact may aggravate unpredictable perimenopausal bleeding. Oral contraceptives offer many benefits for healthy, nonsmoking, perimenopausal women. Oral contraceptive use by women in their 40s has been found to decrease the risk of postmenopausal hip fractures and regularize menses in women with dysfunctional uterine bleeding, reducing the need for surgical intervention for benign menstrual conditions. Use of oral contraceptives also can reduce long-term risk of endometrial and ovarian cancers. There is also good evidence that oral contraceptives relieve vasomotor symptoms in perimenopausal women. Oral contraceptives can be viewed as a strategy not only to improve perimenopausal symptoms, provide effective contraception, and reduce some long-term health risks, but also to enhance the quality of life for perimenopausal women.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (2)
References (53)
- W41071584 via openalex
- W43666124 via openalex
- W1442973484 via openalex
- W1531886711 via openalex
- W1573027078 via openalex
- W1718190240 via openalex
- W1783602832 via openalex
- W1907235146 via openalex
- W1968327793 via openalex
- W1984740500 via openalex
- W1993050841 via openalex
- W2008543198 via openalex
- W2015434610 via openalex
- W2016746021 via openalex
- W2024889666 via openalex
- W2033358136 via openalex
- W2042681394 via openalex
- W2042925173 via openalex
- W2043645968 via openalex
- W2043847089 via openalex
- W2044046825 via openalex
- W2048208535 via openalex
- W2055119652 via openalex
- W2062503593 via openalex
- W2067058076 via openalex
- W2069509517 via openalex
- W2070796663 via openalex
- W2084360197 via openalex
- W2084587826 via openalex
- W2088158971 via openalex
- W2107314134 via openalex
- W2133369207 via openalex
- W2150276481 via openalex
- W2161500703 via openalex
- W2280278461 via openalex
- W2321076352 via openalex
- W2321128171 via openalex
- W2325550927 via openalex
- W2332850056 via openalex
- W2341597406 via openalex
- W2599867508 via openalex
- W2626763965 via openalex
- W2918154310 via openalex
- W3143205803 via openalex
- W4285719527 via openalex
- W6601849366 via openalex
- W6648565529 via openalex
- W6652622951 via openalex
- W6667770567 via openalex
- W6701223439 via openalex
- W6759754431 via openalex
- W6980583568 via openalex
- W7033295059 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK